Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 20,025 shares at $15.48 ($310K) on 2023-08-07, disclosed to the SEC on 2023-08-09.
Scheduled sale ($310k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.48 | 9,742 | $151K | 48.6% |
| 2 | $15.48 | 9,742 | $151K | 48.6% |
| 3 | $16.25 | 541 | $9K | 2.8% |
| Total | $15.50 avg | 20,025 | $310K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-28 | $619K | — | Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |